Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites ATLANTA and SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- ...
The FDA cleared for commercial distribution a diagnostic panel that tests for multiple respiratory viral and bacterial infections on Feb. 3. The BioFire Spotfire Respiratory Panel is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results